Source: Health Canada shortage reports · Updated Jul 20, 2026
Some Cilazapril products are in shortage in Canada (2 of 13 reported products), while others remain available. Your pharmacy may be able to substitute an unaffected manufacturer. The latest estimate for affected products to return is Aug 11, 2026.
An ACE inhibitor used to lower blood pressure and treat heart failure.
Products affected
2 / 13
In shortage since
Nov 26, 2018
Est. full return
Aug 11, 2026
Reports on file
41
Talk to a pharmacist
Pharmacists can substitute an unaffected manufacturer's version, adjust strengths, and in most provinces adapt or renew a prescription on the spot.
Independent services, not affiliated with rxstat; referral fees may apply. Free options exist depending on your province. In an emergency call 911; free health advice at 811.
Shortage history
Shortage history (red bands = periods in shortage).
Reports by product
The DIN is printed on your prescription label.
Active shortage
MYLAN-CILAZAPRIL
5.0MG · TABLET · MYLAN PHARMACEUTICALS ULC
DIN 02283794 · since Jul 2, 2026, est. end Aug 11, 2026 · Disruption of the manufacture of the drug.
Active shortage
INHIBACE
2.5MG · TABLET · HOFFMANN-LA ROCHE LIMITED
DIN 01911473 · since Nov 26, 2018, no end estimate
Resolved
MYLAN-CILAZAPRIL
1MG · TABLET · MYLAN PHARMACEUTICALS ULC
DIN 02283778 · ended Apr 30, 2026 · Disruption of the manufacture of the drug.
Resolved
MYLAN-CILAZAPRIL
2.5MG · TABLET · MYLAN PHARMACEUTICALS ULC
DIN 02283786 · ended Apr 9, 2026 · Disruption of the manufacture of the drug.
Resolved
MYLAN-CILAZAPRIL
2.5MG · TABLET · MYLAN PHARMACEUTICALS ULC
DIN 02283786 · ended Feb 9, 2026 · Disruption of the manufacture of the drug.
Resolved
MYLAN-CILAZAPRIL
5.0MG · TABLET · MYLAN PHARMACEUTICALS ULC
DIN 02283794 · ended Mar 14, 2024 · Regulatory Delays
Resolved
MYLAN-CILAZAPRIL
5.0MG · TABLET · MYLAN PHARMACEUTICALS ULC
DIN 02283794 · ended Jul 26, 2023 · Disruption of the manufacture of the drug.
Resolved
APO-CILAZAPRIL
5MG · TABLET · APOTEX INC
DIN 02291150 · ended Apr 1, 2022 · Disruption of the manufacture of the drug.
Discontinued
PMS-CILAZAPRIL
1.0MG · TABLET · PHARMASCIENCE INC
DIN 02280442
Discontinued
PMS-CILAZAPRIL
5.0MG · TABLET · PHARMASCIENCE INC
DIN 02280469
Discontinued
PMS-CILAZAPRIL
5.0MG · TABLET · PHARMASCIENCE INC
DIN 02280469
Discontinued
PMS-CILAZAPRIL
2.5MG · TABLET · PHARMASCIENCE INC
DIN 02280450
Showing 12 of 41 reports. All reports are on file with Health Canada.
What's happening
Cilazapril is currently affected by 2 active shortage reports filed with Health Canada by MYLAN PHARMACEUTICALS ULC, HOFFMANN-LA ROCHE LIMITED.
The reported cause is: disruption of the manufacture of the drug. Manufacturers must report shortages, but end-date estimates are their own projections and often move.
If your usual product is affected, a pharmacist is the fastest route to a solution: they can dispense an unaffected manufacturer's equivalent when one exists, and in most provinces can adapt doses or substitute a therapeutic alternative without a new appointment.
Cilazapril is classified under “ACE INHIBITORS, PLAIN” (ATC C09AA).
Recent changes
Jul 20, 2026
Estimated end date moved earlier : Nov 24, 2026 → Aug 11, 2026
Common questions
What is Cilazapril used for?
An ACE inhibitor used to lower blood pressure and treat heart failure.
When will Cilazapril be back in stock in Canada?
The latest manufacturer estimate is Aug 11, 2026. Estimates are self-reported and often slip; this page updates automatically when they change.
Why is Cilazapril in shortage?
See the reports above; manufacturers must state a reason (most commonly manufacturing disruption or a surge in demand) when filing with Health Canada.
What can my pharmacist do about it?
Often quite a lot: substitute an equivalent product from an unaffected manufacturer, adjust quantities, or in most provinces adapt or renew prescriptions on the spot. Call your pharmacy before visiting, and call 811 for free health advice.
Email alerts
Get an email when this drug's status changes. Double opt-in, one-click unsubscribe.
Drugs in the same therapeutic class, best-supplied first. These are not automatic substitutes: only your pharmacist or prescriber can judge whether a switch makes sense for you.
Data reflects reports manufacturers are legally required to file with Health Canada, republished with per-drug aggregation by rxstat. Estimated end dates are supplied by manufacturers and frequently change. This page describes drug supply only and is not medical advice; never stop or switch a medication without speaking to your pharmacist or prescriber.